zoledronic acid has been researched along with goserelin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Inoue, K; Iwase, H; Kawazoe, T; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yamamoto, Y; Yoshida, Y | 1 |
| Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M | 1 |
| Gralow, JR | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Ayoub, G; Banal, F; Briot, K; Dougados, M; Roux, C | 1 |
| Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C | 1 |
| Wenz, F | 1 |
| Aebi, S; Gelber, RD | 1 |
| Dong, PW; Li, LN | 1 |
| Casey, R; Gesztesi, Z; Rochford, J | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Clezardin, P; Coleman, R; Gnant, M; Morgan, G | 1 |
| Becker, JT; Binkley, N; Buehring, B; Eickhoff, JC; Lang, JM; Liu, G; Malkovsky, M; McNeel, DG; Staab, MJ; Wallace, M; Wilding, G | 1 |
| Esa, A; Hara, I; Imanishi, M; Inagaki, T; Kajikawa, H; Kitagawa, M; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| D'Amico, AV | 1 |
| Baier, M; Birkholz, K; Hadji, P; Kann, P; Kauka, A; Muth, M; Ziller, M | 1 |
| Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V | 1 |
2 review(s) available for zoledronic acid and goserelin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Effects of bone-targeted agents on cancer progression and mortality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Female; Goserelin; Humans; Imidazoles; Male; Menopause; Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2012 |
10 trial(s) available for zoledronic acid and goserelin
| Article | Year |
|---|---|
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2005 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Long term zoledronic acid during androgen blockade for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Diphosphonates; Goserelin; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Time Factors; Zoledronic Acid | 2010 |
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Drug Administration Schedule; Goserelin; Humans; Imidazoles; Leuprolide; Lymphocyte Count; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; T-Lymphocytes; Zoledronic Acid | 2013 |
Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
Topics: Aged; Androgen Antagonists; Androgens; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Goserelin; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Goserelin; Hormones; Humans; Imidazoles; Middle Aged; Premenopause; Prospective Studies; Tamoxifen; Young Adult; Zoledronic Acid | 2014 |
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
9 other study(ies) available for zoledronic acid and goserelin
| Article | Year |
|---|---|
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
[Two cases of stage IV breast cancer with severe hypercalcemia].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Goserelin; Humans; Hypercalcemia; Imidazoles; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Quality of Life; Tamoxifen; Zoledronic Acid | 2006 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates; Goserelin; Humans; Imidazoles; Male; Osteoporosis; Uveitis, Anterior; Zoledronic Acid | 2008 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |